chronic idiopathic demyelinating polyneuropathy G61.8
Conditions
Interventions
Group 1: Patients with chronic idiopathic demyelinating polyneuropathy, who are treated with Gamunex in daily pratice, will be interviewed with questionnaires.
Sponsors
Grifols Deutschland GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • diagnosed CIDP • signed informed consent • Patients who have completed or discontinued the non-interventional study are not allowed to be re-assigned into the protocoll of the extended observation period. Patients who finished the first study with one year observation period could enclosed to the second Study with 2 year observation period.
Exclusion criteria
Exclusion criteria: • selective IgA deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • change of depression using the Beck Depression Index (BDI) at the beginning of the therapy and every 3 month (duration of observation up to: 144 weeks) • change of fatigue using the Fatigue Severity Scale (FSS) at the beginning of the therapy and every 3 month (duration of observation up to: 144 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Therapeutic benefit assessed by the INCAT Score, WPAI-GH, SF-36 und Hughes Score at the beginning of the therapy and every 3 month (duration of observation up to: 144 weeks) • Safety by documentation of all AEs during this study | — |
Countries
Germany
Contacts
Public ContactDaniel Militz
Grifols Deutschland GmbH
Outcome results
None listed